Guangzhou Kingmed Diagnostics Group Co Ltd (603882.SS) stock: key figures, P/E, revenue and dividend
Health Care · Life Sciences Tools & Services · China · ISIN CNE100002VW1
Price
28.76 CNY
Market cap
13.32 bn CNY
P/E (2025)
–
P/S (2025)
2.21
Dividend yield
3.06 %
Net margin
-2.87 %
Return on equity (ROE)
-2.57 %
Return on assets (ROA)
-1.80 %
Guangzhou Kingmed Diagnostics Group Co Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 7.19 bn CNY | 6.03 bn CNY |
| Gross profit | 2.38 bn CNY | 2.10 bn CNY |
| Operating income | -273.24 m CNY | 242.30 m CNY |
| EBIT | -180.92 m CNY | -166.93 m CNY |
| Net income | -381.24 m CNY | -173.24 m CNY |
| Diluted EPS – continuing operations | -0.82 CNY | -0.37 CNY |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Guangzhou Kingmed Diagnostics Group Co Ltd
Guangzhou Kingmed Diagnostics Group Co., Ltd. provides medical diagnosis services in China. It also provides medical health check-up, medical cold chain logistics, and other services, as well as sells diagnostic products. Guangzhou Kingmed Diagnostics Group Co., Ltd. was founded in 2006 and is headquartered in Guangzhou, China.
More stocks
- Currys PLC (CURY.L)
- Xinyi Solar Holdings Ltd (968.HK)
- Hesai Group Sponsored ADR (HSAI)
- WAFD INC (WAFD)
- Cosmax Inc (192820.KS)
- Worthington Steel, Inc. (WS)
- Cadeler A/S (CADLR.OL)
- RECURSION PHARMACEUTICALS, INC. (RXRX)
- Baldwin Insurance Group, Inc. (BWIN)
- Proto Labs Inc (PRLB)
- Hefei Meiya Optoelectronic Technology Inc (002690.SZ)
- Philip Morris CR A.S. (TABAK.PR)
Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.